Search Results
Results found for "Confo Therapeutics"
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
These nuances define therapeutic potential and side-effect risk. Each mode reshapes both potency and therapeutic window.
- 📰 GPCR Weekly News, January 30 to February 5, 2023
Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets. Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318 GPCR Therapeutics interest’ Addex Strategic Partner Completes Enrollment In Adx71149 Epilepsy Phase 2 Study Part 1 Domain Therapeutics
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
Zhao et al. 2019) together with confocal fluorescence microscopy. This scavenging function should be considered when evaluating the safety and therapeutic efficacy of
- A central alarm system that gates multi-sensory innate threat cues to the amygdala
The identification of unified innate threat pathways may provide insights into developing therapeutic
- Nanobodies as Probes and Modulators of Cardiovascular G Protein-Coupled Receptors
nanobodies with tailored specificities may expand the impact of these tools for both basic science and therapeutic
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics
- Tracking receptor motions at the plasma membrane reveals distinct effects of ligands on CCR5...
However, how these states impact GPCRs biological function and therapeutic targeting remains incompletely
- APEX2/AUR Biosensor: A Powerful Tool for Protein Interaction and Trafficking
; understanding the role of DNAJC13 in GPCR trafficking could profoundly affect the development of therapeutic
- An overview of the compartmentalized GPCR Signaling: Relevance and Implications
compartments and signaling pathways associated with GPCRs holds promise for the development of novel therapeutic Insights into Nuclear G-Protein-Coupled Receptors as Therapeutic Targets in Non-Communicable Diseases GPCRomics: GPCR Expression in Cancer Cells and Tumors Identifies New, Potential Biomarkers and Therapeutic
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development company unlocking the therapeutic
- Immunomodulatory Role of Neuropeptides in the Cornea
maintaining the homeostasis of the ocular surface, alterations in disease settings, and the possible therapeutic
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- 📰 GPCR Weekly News, February 6 to 12, 2023
IPO, raising $161M 3-drug combo leads to 'unprecedented' response in pancreatic cancer models Addex Therapeutics in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics
- Chronic itch: emerging treatments following new research concepts
itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Ottawa, Ontario, Canada, Nov. 30, 2021 -- Orion Biotechnology, a clinical stage company unlocking the therapeutic
- 📰 GPCR Weekly News, July 31 to August 6, 2023
GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Additional Chf 2.7 Million From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics
- Lipid Modulation of a Class B GPCR: Elucidating the Modulatory Role of PI(4,5)P 2 Lipids
interacting with the Glucagon receptor (GCGR), which constitutes an important target for diabetes and obesity therapeutics
- 📰 GPCR Weekly News, November 13 to 19, 2023
identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy Industry News OMass Therapeutics (ANDA) Litigation PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics
- TRPM3 in the eye and in the nervous system - from new findings to novel mechanisms
clear picture is needed to unravel TRPM3's full potential as experimental tool, diagnostic marker and therapeutic
- Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell...
Understanding these processes has important implications for understanding the therapeutic intervention
- Orthosteric vs Allosteric Interactions— and the pHSense Shift in Internalization
Separate effect size from time: Use allosteric modulators to expand therapeutic index and reduce overdose Why It Matters In the CNS, where receptor localization and real-time signaling shape therapeutic outcomes
- Structural basis for receptor selectivity and inverse agonism in S1P5 receptors
Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor
- Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone...
These therapeutic strategies could greatly impact the treatment of CVD with unprecedented benefits which
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
years to uncover the mechanisms of disease before they can even dare to contemplate the development of therapeutic
- GPCR Signaling and mTORC1 Regulation
of mTOR complex 1 (mTORC1) is typically observed in human disease and continues to be an important therapeutic
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
Currently, there is no cure for RP, and the therapeutic options are limited.
- To probe the activation mechanism of the Delta opioid receptor by an agonist ADL5859 started from...
These insights will facilitate further development of therapeutic agents targeting the DOR.Communicated
- A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation
These findings indicate the potential of inhibiting MC4R homodimerization as a therapeutic target to
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
How Structural Biology Informs the Development of Drugs Targeting G Protein-Coupled Receptors ARTICA THERAPEUTICS GPCR Jobs NEW GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
theoretically offer several advantages compared to orthosteric ligands when considered as potential therapeutic other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic



